BDX Stock Gains 25.5% in Six Months: What's Behind the Rally?

BDX has climbed 25.5% over six months, and the rally rests on three named drivers: portfolio realignment after the Life Sciences separation, earnings growth across its high-growth platforms, and a $19 billion U.S. manufacturing partnership agreement.

Management raised fiscal 2026 EPS guidance, and the company returned $3.1 billion to shareholders. Together, those moves signal confidence in near-term earnings power and a willingness to support the stock through capital returns. That is interpretation, but the pairing of a guidance raise with a $3.1 billion payout is the kind of combination that tends to anchor momentum buyers.

The rally is not unchallenged. Zacks flags three headwinds: tariffs, Alaris remediation, and weakness in China vaccines. The 25.5% gain suggests the market is currently weighing the guidance raise and the $19 billion manufacturing commitment more heavily than those risks. Whether that balance holds depends on how much each headwind bites into the raised fiscal 2026 EPS outlook.

The Life Sciences separation leaves BDX as a more focused company, and the six-month move reflects investors rewarding that restructuring alongside the earnings story.